Oral Administration of Chitosan Attenuates Bleomycin-induced Pulmonary Fibrosis in Rats
- Authors
- Kim, You-Seok; Li, Qiang; Youn, Hwa-Young; Kim, Dae Young
- Issue Date
- Sep-2019
- Publisher
- INT INST ANTICANCER RESEARCH
- Keywords
- Bleomycin; chitosan; oral administration; pulmonary fibrosis
- Citation
- IN VIVO, v.33, no.5, pp.1455 - 1461
- Journal Title
- IN VIVO
- Volume
- 33
- Number
- 5
- Start Page
- 1455
- End Page
- 1461
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/1048
- DOI
- 10.21873/invivo.11624
- ISSN
- 0258-851X
- Abstract
- Background/Aim: Idiopathic pulmonary fibrosis (PF) is a fatal disorder of unknown aetiology with limited treatment options. Chitosan has antibacterial, antifungal, antioxidant, antitumour, and anti-inflammatory effects. This study aimed to investigate the effects of chitosan administration on bleomycin (BLM)-induced PF in rats. Materials and Methods: A PF rat model was established by endotracheal instillation of 5 mg/kg BLM; then, chitosan was administered in drinking water for 3 weeks. Histology, cell counts, and cytokine responses in the bronchoalveolar lavage fluid (BALF) and weight measurements (body and lung) were analyzed to assess its therapeutic effects. Results: Chitosan administration tended to reduce transforming growth factor (TGF)-beta 1 and interferon (IFN)-gamma levels in BALF, and histopathological examination confirmed that chitosan attenuated the degree of inflammation and fibrosis in the lung. Conclusion: This study revealed that oral chitosan exhibits potential antifibrotic effects, as measured by decreased proinflammatory cytokine levels and histological evaluation, in a BLM-induced PF rat model.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 바이오나노대학 > 생명과학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.